Literature DB >> 23002429

MDM2 and MDMX: Alone and together in regulation of p53.

Miriam Shadfan1, Vanessa Lopez-Pajares, Zhi-Min Yuan.   

Abstract

p53, a critical tumor suppressor, is activated by various cellular stresses to prevent and repair damages that can lead to tumor development. In response to these stresses, p53 activation can cause very serious cellular effects including permanent cell cycle arrest and cell death. p53 must therefore be very tightly regulated to avoid unnecessary pathological effects. The homologs MDM2 and MDMX have been shown to be the major, essential negative regulators of p53. In normal cells, MDM2 and MDMX suppress p53 activity, but in the event of cellular stress, they themselves must be inhibited so that p53 may respond to the stress. MDM2 and MDMX are known to bind together, and play multifaceted, non-redundant roles in modulating p53 protein activity. Recently, evidence has emerged showing that MDM2 and MDMX most effectively inhibit p53 as a complex, and possibly play non-redundant roles because they must function as one to control p53. In this review, we give an overview of MDM2 and MDMX and discuss a few ways in which they are modified so that p53 may be activated. Lastly, we discuss the non-redundant roles of MDM2 and MDMX and how it is important to investigate the effect on the complex as a whole when investigating either protein.

Entities:  

Year:  2012        PMID: 23002429      PMCID: PMC3448287     

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


  118 in total

1.  Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3.

Authors:  Cynthia LeBron; Lihong Chen; Daniele M Gilkes; Jiandong Chen
Journal:  EMBO J       Date:  2006-03-02       Impact factor: 11.598

2.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

Authors:  Shunbin Xiong; Carolyn S Van Pelt; Ana C Elizondo-Fraire; Geng Liu; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

3.  Regulation of MDMX expression by mitogenic signaling.

Authors:  Daniele M Gilkes; Yu Pan; Domenico Coppola; Timothy Yeatman; Gary W Reuther; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 5.  Regulation of p53 downstream genes.

Authors:  W S el-Deiry
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

6.  Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Authors:  Thomas Leonard Joseph; Arumugam Madhumalar; Christopher J Brown; David P Lane; Chandra S Verma
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

9.  Regulation of autophagy by cytoplasmic p53.

Authors:  Ezgi Tasdemir; M Chiara Maiuri; Lorenzo Galluzzi; Ilio Vitale; Mojgan Djavaheri-Mergny; Marcello D'Amelio; Alfredo Criollo; Eugenia Morselli; Changlian Zhu; Francis Harper; Ulf Nannmark; Chrysanthi Samara; Paolo Pinton; José Miguel Vicencio; Rosa Carnuccio; Ute M Moll; Frank Madeo; Patrizia Paterlini-Brechot; Rosario Rizzuto; Gyorgy Szabadkai; Gérard Pierron; Klas Blomgren; Nektarios Tavernarakis; Patrice Codogno; Francesco Cecconi; Guido Kroemer
Journal:  Nat Cell Biol       Date:  2008-05-04       Impact factor: 28.824

10.  Inhibition of HDM2 and activation of p53 by ribosomal protein L23.

Authors:  Aiwen Jin; Koji Itahana; Kevin O'Keefe; Yanping Zhang
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more
  58 in total

1.  Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.

Authors:  Yiwei Zhang; Xin Zhang; Hua Lu
Journal:  Dev Biol       Date:  2014-09-28       Impact factor: 3.582

2.  p53 protects against LPS-induced lung endothelial barrier dysfunction.

Authors:  Nektarios Barabutis; Christiana Dimitropoulou; Charalampos Birmpas; Atul Joshi; Gagan Thangjam; John D Catravas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-02-20       Impact factor: 5.464

3.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal:  Cell Cycle       Date:  2017-04-05       Impact factor: 4.534

4.  AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.

Authors:  Anna de Polo; Zhongling Luo; Casimiro Gerarduzzi; Xiang Chen; John B Little; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2017-04-01       Impact factor: 6.216

5.  p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization.

Authors:  Daniel K Fox; Scott M Ebert; Kale S Bongers; Michael C Dyle; Steven A Bullard; Jason M Dierdorff; Steven D Kunkel; Christopher M Adams
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-06-03       Impact factor: 4.310

6.  p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.

Authors:  Yang Yang-Hartwich; Roslyn Tedja; Cai M Roberts; Jamie Goodner-Bingham; Carlos Cardenas; Marta Gurea; Natalia J Sumi; Ayesha B Alvero; Carlotta A Glackin; Gil Mor
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

7.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

8.  Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Pharmacol       Date:  2020-02-16       Impact factor: 4.436

9.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.

Authors:  Xiaohong Wu; Li Liang; Liangliang Dong; Zhe Yu; Xiaoqing Fu
Journal:  Mol Biol Rep       Date:  2012-12-18       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.